Neuronal Ceroid Lipofuscinosis: A Common Pathway?

The neuronal ceroid lipofuscinoses are pediatric neurodegenerative diseases with common clinical features. Of the nine clinical variants (CLN1–CLN9), six have been genetically identified. Most variants manifest cell death and dysregulated sphingolipid metabolism, suggesting the proteins defective in these disorders may interact along one pathway. NCL patient-derived cell lines exhibit cell growth and apoptotic defects that reverse following transfection with the wild-type gene. The membrane-bound proteins CLN3, CLN6, and CLN8 complement each other, as do CLN1 and CLN2 proteins, with respect to growth and apoptosis. The CLN2 protein also corrects growth and apoptosis in CLN3-, CLN6-, and CLN8-deficient cell lines. Neither CLN1-deficient nor CLN2-deficient growth defects are corrected by CLN3, CLN6, and CLN8 proteins. CLN2, CLN3, CLN6, and CLN8 proteins co-immunoprecipitate and co-localize to early and/or recycling endosomes and lipid rafts. Additionally, CLN2p and CLN1p co-immunoprecipitate. The work presented supports interactions between NCL proteins occurring at multiple points along one pathway.

[1]  D. Pearce,et al.  The neuronal ceroid lipofuscinoses , 2007, NeuroMolecular Medicine.

[2]  M. Hermansson,et al.  Mass spectrometric analysis reveals changes in phospholipid, neutral sphingolipid and sulfatide molecular species in progressive epilepsy with mental retardation, EPMR, brain: a case study , 2005, Journal of neurochemistry.

[3]  A. VanDongen,et al.  A Galactosylceramide Binding Domain Is Involved in Trafficking of CLN3 from Golgi to Rafts via Recycling Endosomes , 2004, Pediatric Research.

[4]  A. Hoogeveen,et al.  The MTG proteins: chromatin repression players with a passion for networking. , 2004, Genomics.

[5]  P. Filipek,et al.  Seizures, depression and dementia in teenagers with Batten disease , 1993, Journal of Inherited Metabolic Disease.

[6]  A. VanDongen,et al.  Motifs within the CLN3 protein: modulation of cell growth rates and apoptosis. , 2002, Human molecular genetics.

[7]  L. Peltonen,et al.  Neuronal ceroid lipofuscinoses are connected at molecular level: interaction of CLN5 protein with CLN2 and CLN3. , 2002, Molecular biology of the cell.

[8]  A. Amalfitano,et al.  The CLN3 gene is a novel molecular target for cancer drug discovery. , 2002, Cancer research.

[9]  D. Pearce,et al.  The neuronal ceroid lipofuscinoses: mutations in different proteins result in similar disease. , 2002, Neuromolecular medicine.

[10]  T. Autti,et al.  Clinical and neuroradiological diagnostic aspects of neuronal ceroid lipofuscinoses disorders. , 2001, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[11]  C. Leray,et al.  Phospholipid composition in late infantile neuronal ceroid lipofuscinosis , 2000, European journal of clinical investigation.

[12]  G. Cohen,et al.  Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. , 2000, Experimental cell research.

[13]  W. Brück,et al.  Progress in neuropathology of the neuronal ceroid lipofuscinoses. , 1999, Molecular genetics and metabolism.

[14]  D. Sleat,et al.  Specific alterations in levels of mannose 6-phosphorylated glycoproteins in different neuronal ceroid lipofuscinoses. , 1998, The Biochemical journal.

[15]  H. Goebel,et al.  The Neuronal Ceroid‐Lipofuscinoses. Recent Advances , 1998, Brain pathology.

[16]  D. Palmer,et al.  Different patterns of hydrophobic protein storage in different forms of neuronal ceroid lipofuscinosis (NCL, Batten disease). , 1997, Neuropediatrics.

[17]  J. Suopanki,et al.  Sphingolipid activator proteins (SAPs) in neuronal ceroid lipofuscinoses (NCL). , 1997, Neuropediatrics.

[18]  H. Goebel Topical Review: The Neuronal Ceroid-Lipofuscinoses , 1995 .

[19]  M. Baumann,et al.  Immunological studies on sphingolipid activator proteins in the neuronal ceroid-lipofuscinoses. , 1995, Gerontology.

[20]  H. Goebel The neuronal ceroid-lipofuscinoses. , 1995, Journal of child neurology.

[21]  R. Boustany Neurology of the neuronal ceroid-lipofuscinoses: late infantile and juvenile types. , 1992, American journal of medical genetics.

[22]  T. Autti,et al.  Comparison of the clinical courses in patients with juvenile neuronal ceroid lipofuscinosis receiving antioxidant treatment and those without antioxidant treatment. , 1989, Advances in experimental medicine and biology.

[23]  J. Alroy,et al.  Clinical classification of neuronal ceroid-lipofuscinosis subtypes. , 1988, American journal of medical genetics. Supplement.